prof. dr. T.L. (Talitha) Feenstra

Associate professor, economic evaluation of precision medicine

prof. dr. T.L. (Talitha) Feenstra
Telephone:
+31 50 36 32607 (office)
extra phone:
+31 30 274 4387 (RIVM (Monday))
E-mail:
t.l.feenstra rug.nl

Research

  1. 2020
  2. Si, L., Willis, M. S., Asseburg, C., Nilsson, A., Tew, M., Clarke, P. M., Lamotte, M., Ramos, M., Shao, H., Shi, L., Zhang, P., McEwan, P., Ye, W., Herman, W. H., Kuo, S., Isaman, D. J., Schramm, W., Sailer, F., Brennan, A., ... Palmer, A. J. (2020). Evaluating the Ability of Economic Models of Diabetes to Simulate New Cardiovascular Outcomes Trials: A Report on the Ninth Mount Hood Diabetes Challenge. Value in Health, 23(9), 1163-1170. https://doi.org/10.1016/j.jval.2020.04.1832
  3. van der Heijden, A. A., Nijpels, G., Badloe, F., Lovejoy, H. L., Peelen, L. M., Feenstra, T. L., Moons, K. G. M., Slieker, R. C., Herings, R. M. C., Elders, P. J. M., & Beulens, J. W. (2020). Prediction models for development of retinopathy in people with type 2 diabetes: systematic review and external validation in a Dutch primary care setting. Diabetologia, 63(6), 1110-1119. https://doi.org/10.1007/s00125-020-05134-3
  4. Feenstra, T. L., Knies, S., Ramaekers, B. L. T., & Koffijberg, E. (2020). Gezondheids-economische beslismodellen: de stand van zaken en de toekomst. VGE Informatie Bulletin, 24-27. [maart 2020].
  5. 2019
  6. Kent, S., Becker, F., Feenstra, T., Tran-Duy, A., Schlackow, I., Tew, M., Zhang, P., Ye, W., Lizheng, S., Herman, W., McEwan, P., Schramm, W., Gray, A., Leal, J., Lamotte, M., Willis, M., Palmer, A. J., & Clarke, P. (2019). The Challenge of Transparency and Validation in Health Economic Decision Modelling: A View from Mount Hood. Pharmacoeconomics, 37(11), 1305-1312. https://doi.org/10.1007/s40273-019-00825-1
  7. Beulens, J. W., Yauw, J. S., Peelen, L. M., Feenstra, T. L., Moons, K. G., Slieker, R. C., Herings, R. M., Elders, P. J., Nijpels, G., & van der Heijden, A. A. (2019). Prediction models for the risk of diabetic foot in people with type 2 diabetes: a systematic review and external validation study. Diabetologia, 62, S459-S460.
  8. Nijpels, G., Yauw, J., Feenstra, T., Baan, C., Beulens, J., Elders, P., Herings, R., Moons, K., Slieker, R., Peelen, L., & van der Heijden, A. (2019). Prediction of macrovascular events and mortality in people with type 2 diabetes using dynamic modelling of systolic blood pressure: the Hoorn Diabetes Care System cohort. Diabetologia, 62, S573-S573.
  9. Slobbe, L. C. J., Füssenich, K., Wong, A., Boshuizen, H. C., Nielen, M. M. J., Polder, J. J., Feenstra, T. L., & van Oers, H. A. M. (2019). Estimating disease prevalence from drug utilization data using the Random Forest algorithm. European Journal of Public Health, 29(4), 615-621. https://doi.org/10.1093/eurpub/cky270
  10. Feenstra, T. L., & Buskens, E. (2019). Organized Session: Sin Taxes, Their Health and Fiscal Consequences. Applications in OECD and Asian Countries.. Abstract from 13th International Health Economics Association (IHEA) World Congress 2019, Basel, Switzerland.
  11. Wijnen, B. F. M., Thielen, F. W., Konings, S., Feenstra, T., Van der Gaag, M., Veling, W., De Haan, L., Ising, H., Hiligsmann, M., Evers, S. M. A. A., Smit, F., & Lokkerbol, J. (2019). Designing and Testing of a Health-Economic Markov Model for Prevention and Treatment of Early Psychosis. Expert review of pharmacoeconomics & outcomes research. https://doi.org/10.1080/14737167.2019.1632194
  12. Suijkerbuijk, A. W. M., Over, E. A. B., Opsteegh, M., Deng, H., van Gils, P. F., Marinovic, A. A. B., Lambooij, M., Polder, J. J., Feenstra, T. L., van der Giessen, J. W. B., de Wit, G. A., & Mangen, M-J. J. (2019). A social cost-benefit analysis of two One Health interventions to prevent toxoplasmosis. PLoS ONE, 14(5), [0216615]. https://doi.org/10.1371/journal.pone.0216615
  13. Eggleston, K., Chen, B. K., Chen, C-H., Chen, Y. I., Feenstra, T., Iizuka, T., Lam, J. T., Leung, G. M., Lu, J. R., Rodriguez-Sanchez, B., Struijs, J. N., Quan, J., & Newhouse, J. P. (2019). Are Quality-Adjusted Medical Prices Declining for Chronic Disease? Evidence from Diabetes Care in Four Health Systems. National Bureau of Economic Research, Inc, NBER Working Papers: 25971. https://doi.org/10.3386/w25971
  14. Becker, F., Feenstra, T., Pagano, E., & Leal, J. (2019). Choice of Statistical Model for Estimating Health State Utility for Economic Models: A Case Study Using Quality of Life Data from Individuals at High Risk for Diabetes. Abstract from 13th International Health Economics Association (IHEA) World Congress 2019, Basel, Switzerland.
  15. 2018
  16. Palmer, A. J., Si, L., Tew, M., Hua, X., Willis, M. S., Asseburg, C., McEwan, P., Leal, J., Gray, A., Foos, V., Lamotte, M., Feenstra, T., O'Connor, P. J., Brandle, M., Smolen, H. J., Gahn, J. C., Valentine, W. J., Pollock, R. F., Breeze, P., ... Clarke, P. M. (2018). Computer Modeling of Diabetes and Its Transparency: A Report on the Eighth Mount Hood Challenge. Value in Health, 21(6), 724-731. https://doi.org/10.1016/j.jval.2018.02.002
  17. Suijkerbuijk, A. W. M., van Gils, P. F., Bonačić Marinović, A. A., Feenstra, T. L., Kortbeek, L. M., Mangen, M-J. J., Opsteegh, M., de Wit, G. A., & van der Giessen, J. W. B. (2018). The design of a Social Cost-Benefit Analysis of preventive interventions for toxoplasmosis: An example of the One Healthapproach. Zoonoses and Public Health, 65(1), 185-194. https://doi.org/10.1111/zph.12417
Previous 1 2 3 4 Next

ID: 71774